Godx Inc.

Godx Inc. is a minority-owned, small disadvantaged business headquartered in Madison, Wisconsin that specializes in the development of rapid, point-of-care diagnostic tests for infectious disease detection. The company leverages expertise in nucleic acid amplification, sample preparation, and lateral flow detection technologies to create innovative diagnostic solutions that address critical public health and force protection needs. Godx Inc. has established itself as a trusted partner of federal health agencies through its focused mission of enabling quick pathogen identification in resource-limited and operational environments where traditional laboratory infrastructure may be unavailable or impractical.

Godx Inc. has demonstrated significant contract experience with federal agencies, securing two prime definitive contracts totaling approximately $2.9 million. The company received a $1.6 million firm fixed-price contract from the National Institute of Allergy and Infectious Diseases (NIAID) awarded July 1, 2022, for the development of a rapid, low-cost, point-of-care diagnostic test capable of detecting enteric pathogens including cholera, salmonella, and shigella, as well as identifying antibiotic resistance markers directly from stool samples. This contract, which concluded December 31, 2025, was not subject to any set-aside program and focused on enabling prompt treatment while reducing antibiotic over-prescription. More recently, Godx Inc. secured a $1.3 million Small Business Innovation Research (SBIR) Program Phase II contract from the Defense Health Agency, awarded September 15, 2025, for the rapid identification of pathogens from water and wastewater. This firm fixed-price contract, designated as a Total Small Business set-aside, is scheduled for completion January 14, 2028, and directly supports military force protection and public health readiness by deploying advanced pathogen detection capabilities in operational and deployed settings.

Godx Inc. has successfully competed for multiple federal grants from NIAID, demonstrating sustained federal investment in its diagnostic technology platform. The company received a project grant awarded April 23, 2021, concluding March 31, 2023, focused on developing a rapid, point-of-need diagnostic for sexually transmitted infections including chlamydia, gonorrhea, and trichomoniasis, with particular emphasis on identifying antibiotic-resistant gonorrhea strains. This grant supported the development of a rapid, hand-held, low-cost device designed to integrate nucleic acid extraction, amplification, and detection to enable immediate treatment at the initial patient visit. Additionally, Godx Inc. was awarded a second NIAID project grant in September 2023, with an ultimate completion date of August 31, 2025, for the development of a rapid and simple paper-based diagnostic test to detect enteric pathogens in developing world settings. This grant addressed the critical global health challenge of diarrheal disease, which causes approximately 1.5 million child deaths annually, by creating an innovative paper strip test integrating low-cost sample preparation using hollow silica microspheres with multiplexed nucleic acid detection to enable point-of-care diagnosis in resource-limited healthcare environments.

diagnostics, research, biotech, biochemistry, infectious disease, assay development, research and development, microfluidics